Short Interest in HLS Therapeutics Inc. (OTCMKTS:HLTRF) Increases By 792.0%

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 446 shares, a growth of 792.0% from the July 15th total of 50 shares. Based on an average daily trading volume, of 1,133 shares, the days-to-cover ratio is currently 0.4 days.

HLS Therapeutics Stock Down 4.7%

Shares of HLTRF stock traded down $0.14 during trading hours on Thursday, reaching $2.84. 5,200 shares of the company’s stock were exchanged, compared to its average volume of 876. HLS Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $4.02. The business has a fifty day moving average price of $3.06 and a 200-day moving average price of $3.21.

HLS Therapeutics Company Profile

HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.

The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.